{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T13:51:40Z","timestamp":1746712300425,"version":"3.40.5"},"reference-count":15,"publisher":"American Academy of Pediatrics (AAP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVES:<\/jats:title><jats:p>The objective was to determine if shorter intravenous (IV) antibiotic (&amp;lt;7 days) for nontyphoidal Salmonella bacteremia (NTS-B) is noninferior to longer (\u22657 days) in terms of 30-day emergency department (ER) or rehospitalization in healthy children.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>A retrospective observational study of otherwise healthy children admitted to a children\u2019s hospital in the United States from 2006 to 2017 with NTS-B was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Of 231 patients reviewed, 51 patients had NTS-B. Median IV duration for all patients was 5 days (range 2\u201317 days). The short-duration group (SDG) (&amp;lt;7 days; N = 32) had a median of 4 days (range 2\u20136 days) of IV antibiotics versus a median of 9 days (range 7\u201317 days) in the long-duration group (LDG) (\u22657 days; N = 19). The hospital length of stay in the SDG was 3.5 days versus 7 days in the LDG (P &amp;lt; .001). The SDG was significantly noninferior to the LDG in terms of ER visits or hospital readmissions within 30 days (absolute risk difference 5.3%; 95% confidence interval \u221216% to \u22125%), with only 1 child in the LDG returning to the ER.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>IV antibiotic durations for NTS-B in otherwise healthy children were variable within our study group. Shorter courses (&amp;lt;7 days) of IV antibiotics were noninferior to longer courses in healthy children and reduced hospital stay. ER visits and readmissions were rare, and there was no association between IV treatment duration and risk of relapse. Prospective studies are needed to study the safety of shorter courses, but given the absence of evidence favoring longer courses, shorter courses can be considered.<\/jats:p><\/jats:sec>","DOI":"10.1542\/hpeds.2019-0231","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T14:16:02Z","timestamp":1575296162000},"page":"993-997","source":"Crossref","is-referenced-by-count":3,"title":["IV Antibiotic Durations for Nontyphoidal<i>Salmonella<\/i>Bacteremia"],"prefix":"10.1542","volume":"9","author":[{"given":"Lauren M.","family":"Hess","sequence":"first","affiliation":[{"name":"Department of Pediatrics,"},{"name":"Texas Children\u2019s Hospital, Houston, Texas; and"},{"name":"Baylor College of Medicine, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany","family":"Burdick","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles G.","family":"Minard","sequence":"additional","affiliation":[{"name":"Dan L. Duncan Institute for Clinical Research,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankhi","family":"Dutta","sequence":"additional","affiliation":[{"name":"Department of Pediatrics,"},{"name":"Texas Children\u2019s Hospital, Houston, Texas; and"},{"name":"Baylor College of Medicine, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2019,12,1]]},"reference":[{"issue":"6","key":"2021120817070795300_B1","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3201\/eid2106.140999","article-title":"Global burden of invasive nontyphoidal Salmonella disease, 2010(1)","volume":"21","author":"Ao","year":"2015","journal-title":"Emerg Infect Dis"},{"volume-title":"Foodborne Diseases Active Surveillance Network (FoodNet): FoodNet 2015 Surveillance Report (Final Data)","year":"2017","author":"CDC","key":"2021120817070795300_B2"},{"issue":"6","key":"2021120817070795300_B3","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1542\/peds.65.6.1125","article-title":"Treatment of Salmonella gastroenteritis with ampicillin, amoxicillin, or placebo","volume":"65","author":"Nelson","year":"1980","journal-title":"Pediatrics"},{"issue":"7","key":"2021120817070795300_B4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/cid\/civ1221","article-title":"Persistent infections by nontyphoidal Salmonella in humans: epidemiology and genetics","volume":"62","author":"Marzel","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021120817070795300_B5","volume-title":"Nontyphoidal Salmonella Bacteremia","author":"Hohman","year":"2017","edition":"15 ed."},{"key":"2021120817070795300_B6","first-page":"711","article-title":"Salmonella infections","volume-title":"Red Book 2018: Report of the Committee on Infectious Diseases","author":"AAP","year":"2018","edition":"31 ed."},{"issue":"suppl 1","key":"2021120817070795300_B7","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.ijantimicag.2007.06.017","article-title":"Short antibiotic treatment courses or how short is short?","volume":"30","author":"Rubinstein","year":"2007","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"2021120817070795300_B8","first-page":"94","article-title":"Duration of antimicrobial therapy for non-typhoid Salmonella bacteremia in healthy children","volume":"35","author":"Yen","year":"2002","journal-title":"J Microbiol Immunol Infect"},{"issue":"10","key":"2021120817070795300_B9","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/0009922814540792","article-title":"The clinical outcomes of antimicrobial therapy in pediatric patients with nontyphoid salmonellosis with different levels of severity","volume":"53","author":"Hu","year":"2014","journal-title":"Clin Pediatr (Phila)"},{"issue":"10","key":"2021120817070795300_B10","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/INF.0b013e318127189b","article-title":"Nontyphoidal Salmonella bacteremia in previously healthy children: analysis of 199 episodes","volume":"26","author":"Tsai","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"2021120817070795300_B11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/clinids\/20.4.917","article-title":"Short course of ofloxacin for treatment of multidrug-resistant typhoid","volume":"20","author":"Tran","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2021120817070795300_B12","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/infdis\/jiw415","article-title":"Antimicrobial resistance among nontyphoidal Salmonella isolated from blood in the United States, 2003-2013","volume":"214","author":"Angelo","year":"2016","journal-title":"J Infect Dis"},{"issue":"3","key":"2021120817070795300_B13","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1128\/AAC.01333-10","article-title":"Antimicrobial resistance among invasive nontyphoidal Salmonella enterica isolates in the United States: National Antimicrobial Resistance Monitoring System, 1996 to 2007","volume":"55","author":"Crump","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2021120817070795300_B14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.qco.0000186851.33844.b2","article-title":"Recent trends in the epidemiology of non-typhoid Salmonella and antimicrobial resistance: the Israeli experience and worldwide review","volume":"18","author":"Weinberger","year":"2005","journal-title":"Curr Opin Infect Dis"},{"issue":"12","key":"2021120817070795300_B15","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/00006454-199912000-00009","article-title":"Non-typhi Salmonella bacteremia in children","volume":"18","author":"Zaidi","year":"1999","journal-title":"Pediatr Infect Dis J"}],"container-title":["Hospital Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article-pdf\/9\/12\/993\/815645\/hpeds_2019-0231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article-pdf\/9\/12\/993\/815645\/hpeds_2019-0231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T10:19:22Z","timestamp":1665137962000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article\/9\/12\/993\/26740\/IV-Antibiotic-Durations-for-Nontyphoidal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":15,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,1]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/hpeds.2019-0231","relation":{},"ISSN":["2154-1663","2154-1671"],"issn-type":[{"type":"print","value":"2154-1663"},{"type":"electronic","value":"2154-1671"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}